Survival in B-Cell Primary Ocular Lymphoma 1997–2014: A Population-Based Study

Abstract

This study sought to explore the prognostic factors in a large retrospective cohort of patients with B-cell primary ocular lymphoma (POL) from the Surveillance, Epidemiology, and End Results database. There were 2778 patients with B-cell POL whose complete clinical information was listed in the Surveillance, Epidemiology, and End Results database between 1997 and 2014. The epidemiology, therapeutic measures, and clinical characteristics were listed as descriptive statistics. Survival analysis was conducted by univariate and multivariable Cox regression models. Multivariate analysis identified age, lymphoma subtype, primary lesion, and radiation status as independent prognostic factors. For indolent lymphoma, radical treatment, especially intravenous chemotherapy, should be avoided. For invasive lymphoma, chemotherapy combined with full orbital irradiation is recommended. Radiotherapy alone or in combination with chemotherapy is superior to chemotherapy alone. These differences were statistically significant (p<0.05). Radiation brings benefits, with tolerable neurotoxicity, to patients with invasive B-cell POL. Radical tumor treatment may not be needed for patients with indolent B-cell POL.

Incidence and Survival Rates of Primary Ocular Lymphoma: A Population-Based Study

“…The increase in the incidence has been hypothesized to be linked to the increased number of immunosuppressed and immunodeficient individuals, increased life expectancy, and improvement of diagnostic tools 1,4 . Few reports studied the prognostic factors of the tumor 2,5 . They found that individuals aged ≥60 years, diffuse large B-cell type lymphoma, and nonconjunctival tumors were all associated with poorer survival rate 2,5 .…”

“…Few reports studied the prognostic factors of the tumor 2,5 . They found that individuals aged ≥60 years, diffuse large B-cell type lymphoma, and nonconjunctival tumors were all associated with poorer survival rate 2,5 . Liu and Zheng 5 used the Surveillance, Epidemiology, and End Results (SEER) database for the period between 1973 and 2014 to study POL.…”

“…They found that the incidence was 0.48/100,000 individuals. Moreover, the 10-year overall survival for patients aged ≥60 years compared with younger patients was 36.2% and 75.8%, respectively 5 . We aimed in this study to explore the updated incidence and survival rates of POL.…”

Ocular adnexal marginal zone lymphoma (OAMZL)

“…OAMZL is an indolent disease, with a slow progression or stable disease without any treatment. The median OS time is about 159 months (10-years OS 54,7%) in patients treated with radiotherapy in combination with chemotherapy, 103 months (10years OS 42,6%) in patients treated with chemotherapy only, 93 months (10-years OS 36,8%) in patients treated with radiotherapy only and 60 months (32,5%) in patients without any treatment (Liu et al, 2018). Local recurrence is common, with 5-years relapse free survival rates of 65%; recurrence in the contralateral orbit is a frequent event after radiotherapy.…”

Investigation of epidemiological characteristics and development of a nomogram to predict survival in primary ocular adnexal lymphoma

“…5,6 The incidence of ocular lymphoma is low due to the lack of lymphoid tissue, and the majority of cases are primary. 7,8 Primary ocular lymphomas (POL) can be intraocular or adnexal in location. Ocular adnexal lymphoma is the most common primary orbital malignancy in adults.…”